Evidence map›Paper›PMID 39048749›Full record

ArticleEsophagus : official journal of the Japan Esophageal Society2024

The implementation status of prehabilitation during neoadjuvant chemotherapy for patients with locally advanced esophageal cancer: a questionnaire survey to the board-certified facilities in Japan.

Tsuyoshi Harada, Tetsuya Tsuji, Takuya Fukushima, Tomohiro Ikeda, Shusuke Toyama, Nobuko Konishi, Hiroki Nakajima, Katsuyoshi Suzuki, Keiji Matsumori, Takumi Yanagisawa and 9 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Esophagus : official journal of the Japan Esophageal Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Clinical mechanism of muscle mass loss during neoadjuvant chemotherapy in older patients with esophageal cancer: a prospective cohort study.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Tsuyoshi HaradaDepartment of Rehabilitation Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. tsuyoshi6167@gmail.com.ORCID 0000-0003-4459-8262
Tetsuya TsujiDepartment of Rehabilitation Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Takuya FukushimaFaculty of Rehabilitation, Kansai Medical University, Hirakata, Osaka, Japan.
Tomohiro IkedaDepartment of Rehabilitation Medicine, Okayama University Hospital, Okayama, Okayama, Japan.
Shusuke ToyamaDepartment of Physical Therapy Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.
Nobuko KonishiDepartment of Rehabilitation Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Hiroki NakajimaDepartment of Rehabilitation, Nagoya University Hospital, Nagoya, Aichi, Japan.
Katsuyoshi SuzukiDivision of Rehabilitation Medicine, Shizuoka Cancer Center, Nagaizumi, Shizuoka, Japan.
Keiji MatsumoriDepartment of Rehabilitation, Shinshu University Hospital, Matsumoto, Nagano, Japan.
Takumi YanagisawaDepartment of Rehabilitation Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Kakeru HashimotoDepartment of Rehabilitation, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
Hitoshi KagayaDepartment of Rehabilitation, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
Sadamoto ZendaDepartment of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Takashi KojimaDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Takeo FujitaDepartment of Esophageal Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Junya UenoDepartment of Rehabilitation Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Nanako HijikataDepartment of Rehabilitation Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Aiko IshikawaDepartment of Rehabilitation Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Ryuichi HayashiDepartment of Rehabilitation Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrehabilitation during neoadjuvant therapy has the potential to improve clinical outcomes. However, information on its global dissemination status is limited. This Japanese nationwide survey investigated the implementation status of and barriers to prehabilitation during neoadjuvant chemotherapy (NAC) for patients with locally advanced esophageal cancer in hospitals.

methodsThis multicenter nationwide survey was conducted by post. The eligible facilities were 155 Japanese hospitals that had been certified within the last 10 years as authorized institutes for board-certified esophageal surgeons by the Japan Esophageal Society. We administered an original questionnaire to investigate the current status of prehabilitation during NAC.

resultsThe response rate was 75% (117/155 facilities). Forty-six facilities (39%) provided prehabilitation during NAC. The most frequently selected reasons for not providing or providing insufficient prehabilitation were lack of human resources, issues with the reimbursement of medical fees, difficulty in providing continuous prehabilitation during repeated inpatient and outpatient care, the lack of established standard prehabilitation programs, challenges in providing multidisciplinary prehabilitation, and difficulty in managing physical symptoms.

conclusionWe observed that the implementation rate of prehabilitation during NAC was low. Critical reasons were not only the lack of medical resources but also the lack of evidence-based standard prehabilitation programs during NAC and the lack of evidence for how to continuously deliver prehabilitation during NAC to patients with physical symptoms.

Indexed as

Esophageal NeoplasmsNeoadjuvant TherapyChemotherapy, AdjuvantFemaleHumansJapanMalePreoperative ExerciseSurveys and QuestionnairesImplementation statusNationwide surveyNeoadjuvant chemotherapyPrehabilitation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.